AUTHORS
Zhengwei Tan, MD, Nanxi Dong, MD2, Nana Zhou3, Hangchao Li4, Dijiong Wu, MD,PhD5, Baodong Ye, MD, PhD6, Wenbin Liu, MD,PhD7
AFFILIATIONS
1 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
2 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China
3 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
4 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
5 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
6 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
7 The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China
ABSTRACT
Background: Parous female donors (PFDs), sensitized to paternal HLA alloantigens during gestation, have been associated with an elevated risk of acute graft-versus-host disease (GVHD) and non-relapse mortality in hematologic malignancies, a phenomenon termed the "PFD effect". Whether the PFD effect significantly modulates transplant outcomes in severe aplastic anemia (SAA), a non-malignant condition dependent on durable engraftment and minimal GVHD, remains incompletely defined.
Methods: We conducted a retrospective cohort analysis of 156 consecutive SAA patients who received haploidentical hematopoietic stem cell transplantation (haplo-HSCT) at a single center between January 2018 and December 2024. Patients were stratified into three groups: parous female donor (PFD, n=22), nulliparous female donor (NFD, n=44), and young male donor (YMD, n=90). The primary endpoints were overall survival (OS) and GVHD-free/relapse-free survival (GRFS). Secondary endpoints included engraftment, primary graft failure, acute and chronic GVHD, and CMV/EBV reactivation. Multivariable Cox proportional hazards regression was performed to adjust for confounders.
Results: Hematopoietic engraftment was comparable across the three groups. The cumulative incidence of any-grade aGVHD was marginally higher in the PFD (54.5%) and NFD (50.0%) groups than in the YMD group (32.2%; p=0.049), but grade II-IV aGVHD and cGVHD did not differ significantly. At a median follow-up of 19 months, 3-year OS was 77.2% for PFD, 88.6% for NFD, and 73.3% for YMD. In multivariable analysis, NFDs were an independent protective factor for OS compared with YMDs (HR 0.35; 95%CI 0.18-0.69; p=0.002), whereas PFDs were independently associated with inferior OS (HR 1.62; 95%CI 1.15-2.28; p=0.006). Very severe aplastic anemia (HR 1.68; p=0.012) and donor-specific antibody positivity (HR 1.85; p<0.001) were also independent risk factors, while the FABT regimen was protective (HR 0.55; p<0.001).
Conclusions: In SAA patients receiving haplo-HSCT, the classical PFD effect persists in the non-malignant setting, with PFDs conferring independently worse OS and NFDs conferring a survival advantage. These findings indicate that donor parity and age, rather than parity alone, represent actionable determinants of transplant success and should inform risk-adapted donor selection strategies.
DISCLOSURES
Wenbin Liu, MD,PhD: No relevant conflicts of interest to declare.